In some studies, it was claimed that dual-ligand modification could increase targeting selectivity or specificity; Saul et al. [51] modified liposomes with folic acid and a monoclonal antibody against an epidermal growth factor receptor (EGFR) for targeting tumor cells in a selective manner to reduce off-targeting. Here, EGFR is linked to neoplasm.